In the guidelines for Pharmaceutical Research and Evaluation of Human Stem Cell Products (Trial) (2023), the CDE underscores a fundamental principle: the quality of production materials directly dictates the safety and efficacy of the final medicinal product. As regulatory requirements from the FDA, EMA, and NMPA increasingly converge, the selection of raw materials has evolved into a high-stakes strategic decision. It is no longer merely about "supporting cell growth"; it is about ensuring IND/BLA submission success, supply chain resilience, and long-term commercial viability. Therefore, as the most critical material in cell and gene therapy (CGT) production, media selection by companies has moved beyond the basic functional requirement of "supporting cell growth" towards a more comprehensive framework that balances product risk control, component transparency, and process compatibility.

With the landmark approvals of Mesenchymal Stem Cell (MSC) therapies in China and the US in 2025, the drug development and clinical application of MSCs have entered a phase of rapid expansion. In this context, selecting appropriate MSC culture media has become a key technical development for cell therapy companies. This article analyses the risk profiles of MSC media and demonstrates how the 3D FloTrix™ Serum-Free Basal Medium (RMZ112) provides a "submission-ready, scalable, and auditable" solution.

Regulatory Consensus: Minimising Animal-Derived Risks

To mitigate the risk of contamination by adventitious agents, major global medicines regulators have set stringent requirements on the use of animal-derived materials in cell and gene therapy products:

1. FDA (2020), in Chemistry, Manufacturing, and Control (CMC) Information for Human Gene Therapy INDs, states that the use of animal-derived materials (e.g., foetal bovine serum) should be avoided wherever possible due to the potential introduction of viruses, prions, and other adventitious agents. If their use is necessary, sufficient justification must be provided, along with comprehensive risk control measures, including source control, testing, and virus inactivation/removal.
2. EMA (2006), in the Guideline on Human Cell-based Medicinal Products, clearly recommends prioritising culture systems free of animal-derived components. The use of animal-derived constituents, such as foetal bovine serum (FBS), should be avoided to reduce transmission risks, including BSE/TSE.
3. CDE (2023), in the guidelines for Pharmaceutical Research and Evaluation of Human Stem Cell Products (Trial), further emphasises that serum should be avoided as far as possible in the production process. If human or animal-derived biological materials, such as human platelet lysate (hPL), are used, complete documentation of the source, quality control data, and virus safety validation results must be provided.

Systems containing animal-derived components, such as FBS or BSA, are inherently high-risk in clinical submissions. Even after virus inactivation processes, non-enveloped viruses (e.g., parvovirus B19) may evade clearance by conventional methods (ICH Q5A (R2)), posing significant risks to patient safety. For biologically sourced components, "complete virus safety evidence" is now mandatory for IND submissions, and products lacking systematic testing will face direct regulatory obstacles.
Based on the different media component types available on the market, the following analysis summarises the risk profile and quality control complexity for these three major categories of media components.

The Core Principle: Source Avoidance vs. Remediation

In the rigorous field of regulatory science, the maxim "prevention is superior to remediation" carries the greatest weight. Mitigating biological risks at the source is significantly more efficient, reliable, and cost-effective than attempting to remove or inactivate contaminants post-production.

The Evolution of MSC Culture: From FBS to hPL
The shift away from traditional methods began in earnest around 2010. A growing body of scientific literature began comparing hPL—often termed a "serum substitute"—with Foetal Bovine Serum (FBS). These studies reached a definitive consensus: hPL and animal serum-free media perform as well as, or often better than, FBS in promoting MSC proliferation, whilst offering a vastly superior safety profile.
This scientific validation catalysed the development of the first generation of commercial serum-free products. Initially adopted by research institutions and biotech firms for preclinical studies, these media soon faced the ultimate test: clinical-grade standardisation.

2015: The Industrial Inflexion Point
The market reached a pivotal milestone with the approval of the first MSC-based therapies. Leading the way were the EU (2015, Alofisel) and Japan (2016, Temcell), followed closely by the US FDA, which strengthened its oversight and explicitly championed animal component-free systems.
The year 2015 remains a landmark for the industry; it marked the transition of serum-free media from a "research preference" to a global industrial standard. Since then, the commercial application of MSC serum-free media has entered an exponential growth phase, driven by the need for compliance with clinical-grade standards.

The Current Landscape: Balancing Performance and Compliance
While the industry’s long-term objective is the adoption of fully chemically defined media—to eliminate immunogenicity and batch-to-batch variability—these formulations still face significant hurdles in terms of culture performance and prohibitive costs. Consequently, serum-free media supplemented with high-quality hPL remains the current mainstream choice and the default standard for the cell therapy industry.

Navigating a Mature Market: A Strategy for Quality Control
As the market for MSC serum-free media matures, the number of suppliers has increased, making scrutiny essential. "Animal origin-free" (AOF) claims must be verified, not merely accepted. We recommend a three-tiered quality control strategy:

• Document Review: Mandating formal AOF declarations from all suppliers.
• On-site Audits: Rigorous inspection of manufacturing processes to ensure that secondary raw materials and workflows remain free from animal-origin contamination.
• In-house Verification: Utilising precise analytical methods, such as ELISA for Bovine Serum Albumin (BSA) detection or mass spectrometry for full proteomic profiling, to definitively confirm the absence of animal-derived components.

By adopting this multi-faceted approach, companies can make informed, risk-controlled decisions supported by conclusive evidence.

Comparative Analysis: Quality Control in Practice

Evidence-based selection is crucial. The following table illustrates how stringent internal standards differentiate high-tier media from standard commercial offerings:

Compliance Quality Control System: Building a Safety Baseline Through Comprehensive Virus Detection

In today’s mature MSC serum-free media market, true competitive advantage is no longer found in raw material sourcing alone. Instead, it lies in the robustness of the quality control closed-loop: an integrated system spanning "raw material screening", "production control", and "finished product testing".
Within this framework, the rigour and comprehensiveness of virus detection serve as the indispensable baseline for ensuring patient safety and securing successful clinical submissions.

Core Raw Material Screening: Eliminating Risks at the Source

As a primary component, hPL represents the first critical checkpoint for compliance. Due to global variations in blood product regulations and supply scarcity, some hPL-containing media on the market suffer from opaque origins or incomplete viral screening. This lack of transparency poses significant risks during clinical IND/BLA reviews.

High-quality, compliant hPL must satisfy three criteria:

▪️Certified Compliant Channels: Blood collection centres are officially certified in the source country, or blood product manufacturing units are registered with international authoritative bodies (e.g., U.S. AABB accreditation, EU EudraCT (European Union Drug Regulating Authorities Clinical Trials Database), or registered blood banks).

▪️Rigorous Tiered Donor Screening: Donors must pass "transfusion-grade" basic screening, supplemented according to regulatory requirements:

• Globally Mandatory Screening Items (Regulatory Consensus): HIV-1/2, HBV, HCV, Syphilis (TP), HTLV-I/II.
• Region-Specific Supplementary Items (Based on Epidemiology): Such as West Nile Virus, Zika Virus (Americas/Africa), Trypanosoma cruzi (Latin America), and those common for clinical-grade products like EBV, CMV.

▪️Standardised Collection Procedures: Compliance with Good Venipuncture Practice (GVP) and local ethical requirements.

High-risk/non-compliant sources to avoid include:

• Clinically discarded platelets were collected independently.
• "Mixed platelet" products without clear donor information and screening records.
• Human-derived materials from uncertified or unregistered channels.

1.Production Control: Maintaining Cleanliness in the Manufacturing Process
Even the compliant raw materials can be compromised by a substandard manufacturing environment. Secondary or cross-contamination is a constant threat that must be managed through stringent facility standards. Industrial-grade media production should adhere to the following benchmarks:

• Certified Management Systems: Manufacturing should occur on platforms certified to ISO 9001 and ISO 13485 standards.
• Controlled Environments: Production must take place within a GMP or GMP-like cleanroom, with a recommended cleanliness level no lower than ISO Class 8.
• Aseptic Processing: Every batch must undergo terminal 0.22 μm sterile filtration to ensure the final product is free from microbial life.
• Antibiotic-Free Formulation: High-quality media should be formulated without antibiotics. Their presence can mask underlying microbial contamination and potentially interfere with inherent cell functions, leading to unreliable clinical data.

The differences between clinical-grade media and standard commercial offerings often lie in the "details" of the specifications. The following data highlights how stringent internal controls eliminate residues that could otherwise jeopardise a regulatory filing.

Final Product Testing: Providing Ultimate Proof with the Strictest Standards

In the current market, some hPL-containing culture media rely exclusively on the initial viral screening of raw material donors as proof of final product safety. However, this approach carries significant regulatory and biological risks.
In accordance with FDA risk-control principles, certain viruses—such as CMV and EBV—may be latent in donors. These can remain undetected by routine serological screening, yet they pose a credible risk of reactivation during the in vitro cell expansion phase.

Establishing a Robust Safety Barrier

Regulatory authorities strongly recommend that final products undergo verification using more sensitive Nucleic Acid Testing (NAT). This is particularly critical when MSCs constitute the final medicinal product, requiring multi-viral testing in compliance with standards such as the Chinese Pharmacopoeia.
As a core raw material, the culture medium must pass comprehensive viral screening to prevent the introduction of adventitious agents into the production pipeline.

Prioritising Transparency

When selecting a medium, companies should prioritise suppliers that provide batch-specific viral testing reports. In the absence of such data, the therapy developer must conduct batch-wise testing independently. A comprehensive screening panel should include, but is not limited to:

• Blood-borne pathogens: HBV, HCV, HIV-1/2, and Syphilis (TP).
• Latent/Reactivating viruses: CMV, EBV, and HHV-6/7/8.

Other clinical risks: HPV 16/18, HAV, HAdV, B19, and BKV.
A medium should only be released for GMP production once compliance across this entire panel is analytically confirmed.MSC Serum-Free Culture Medium Core Quality Parameter Compliance Checklist

To assist cell therapy companies in rapidly assessing clinical readiness, we have compiled a checklist of 12 non-exempt inspection items. This list incorporates the latest edition of the Chinese Pharmacopoeia, proposed 2025 standards, NMPA review practices, and international regulatory consensus.

3D FloTrix™ MSC Serum Free Culture Medium: Providing Reliable Assurance for Clinical-Grade MSC Expansion

In the competitive landscape of Cell and Gene Therapy (CGT), a high-quality, serum-free culture medium is more than a nutrient source; it is the cornerstone of a successful regulatory submission and efficient commercial production.
Leveraging the 3D Cell Intelligent Manufacturing Platform, CytoNiche provides comprehensive solutions for the large-scale preparation of CGT products. Having assisted numerous clients with IND applications and contributed to the approval of China’s first stem-cell drug, we understand that the quality and compliance documentation of a medium directly dictates the pace, risk profile, and ultimate success of the clinical journey.

The 3D FloTrix™ Serum Free Medium (RMZ112-PYJ & RMZ112-B) Mesenchymal Stem Cell is developed in strict accordance with cGMP standards. Manufactured on a platform certified to ISO 9001 and ISO 13485, every batch undergoes rigorous control to ensure all raw materials are of non-animal origin.
At the core raw‑material level, the compliant‑source hPL is meticulously selected, and the internal virus‑safety control standards far exceed common industry practice, incorporating comprehensive Nucleic Acid Testing (NAT) for 16 human viruses, including CMV, EBV, HBV, HCV, HIV‑1/2. This exhaustive protocol significantly enhances regulatory acceptance, aligns with IND/BLA documentation requirements, and reduces uncertainty for our partners.
As the essential “passport” for drug submission and commercialisation, a complete quality‑documentation system is indispensable. CytoNiche provides clients with a full suite of records to support every stage of the application process:

1. Animal-Origin-Free/Xeno-Free Declaration Documents

• Clearly indicate that the culture medium contains no animal-derived materials such as FBS or BSA, or any exogenous/xenogeneic proteins.
• The declaration is reviewed and officially stamped by the company’s Quality Department, carrying legal validity.

2. Virus Safety and Quality Control Documents

• Virus testing reports (customisable reports available).
• Certificate of Analysis (COA) for each finished batch (covering full physical, chemical, microbiological, and functional specifications).

3. Full-Chain Quality Control and Management Documents

• Manufacturer’s GMP certificate and ISO 13485 certification.
• Raw material batch traceability records (traceable to platelet donors/recombinant raw material manufacturers).
• Device History Record (DHR), Device Master Record (DMR), and complete Quality Testing Report (COA).
• Stability study reports (accelerated + long-term stability, covering the entire shelf-life period).
• 3D FloTrix™ Serum Free Medium for MSCs has been successfully filed with the U.S. FDA as a Drug Master File (DMF No.: 038476). This filing allows clients to reference our high-quality manufacturing data directly in their submissions, drastically reducing the time required for data preparation.

(Image: 3D FloTrix™ Serum Free Medium for MSCs & 3D FloTrix™ Serum Free Medium STANDARD)

In large-scale commercial manufacturing, operational complexity is a significant driver of cost and risk. 3D FloTrix™ RMZ112 is engineered to eliminate these bottlenecks. The formulation requires no additional growth factor supplementation or vessel coating/surface treatments before use, facilitating a truly "plug-and-play" experience.
This streamlined approach provides seamless support for both traditional 2D planar culture and advanced 3D microcarrier suspension systems. From primary isolation through to continuous passing, there is no requirement to switch culture media. This consistency greatly simplifies the operational workflow and reduces the regulatory complexity associated with process changes during development.
A reduction in biological risk should not necessitate a compromise in expansion efficiency. Parallel testing under identical culture conditions—comparing planar culture and microcarrier suspension culture of Umbilical Cord-derived MSCs (UCMSCs)—demonstrates the clear competitive advantage of the RMZ112 series.

Key Performance Indicators:

1. Superior Proliferation: The RMZ112 series significantly outperforms competing products containing hPL, BSA, or chemically defined formulations in terms of total cell yield.
2. Stability Across Passages: Cells maintained in RMZ112 exhibit exceptional phenotypic stability and consistent doubling times over successive passages, meeting the stringent demands of large-scale manufacturing.
3. Reduced Risk Profile: By eliminating the need for animal-derived components, the series substantially reduces the risk of adventitious agents while maintaining the high-efficiency growth kinetics required for commercial viability.

Conclusion

As MSC therapies progress from clinical exploration to regulated medicinal products, the role of culture media has fundamentally evolved. No longer a background consumable, media selection now sits at the centre of CMC strategy, directly influencing product safety, regulatory confidence, and development continuity. With global regulators increasingly aligned around risk-based control, avoidable biological risks—particularly those associated with animal-derived materials and inadequate viral safety evidence—are becoming unacceptable in clinical submissions. 
In this environment, performance alone is insufficient. Culture media must be transparent, traceable, and demonstrably submission-ready. Companies that adopt compliant, audit-resilient media early in development are better positioned to reduce regulatory uncertainty, avoid late-stage process changes, and sustain scalable manufacturing. Ultimately, success in MSC development is determined not only by biological performance but also by disciplined material selection that withstands regulatory scrutiny throughout the entire product lifecycle.

References

AABB. (2024). Standards for blood banks and transfusion services (34th ed.).
Center for Drug Evaluation, NMPA. (2023). Guidelines for pharmaceutical research and evaluation of human stem cell products (trial).
Center for Food and Drug Inspection, NMPA. (2025). Inspection guide for the production of cell therapy products.
European Medicines Agency. (2006). Guideline on human cell-based medicinal products (EMEA/CHMP/410869/2006).
Food and Drug Administration. (2007). Eligibility determination for donors of human cells, tissues, and cellular and tissue-based products (HCT/Ps): Guidance for industry.
Food and Drug Administration. (2020). Chemistry, manufacturing, and control (CMC) information for human gene therapy investigational new drug applications (INDs): Guidance for industry.
International Council for Harmonisation. (2023). ICH Q5A(R2): Viral safety evaluation of biotechnology products derived from cell lines of human or animal origin.
International Organization for Standardization. (2022). ISO 20399: Biotechnology—Ancillary materials present during the production of cellular therapeutic products.
Ministry of Industry and Information Technology of the People’s Republic of China. (2007). *HG/T 3935-2007: Mammalian cell culture medium*.
National Pharmacopoeia Committee. (2020). Pharmacopoeia of the People’s Republic of China.
Standards Administration of China & China Association for Standardization. (2025). *T/CAS 1139-2025: Guidelines for quality control of mesenchymal stem cell preparations*.
Standards Administration of China & China Quality Association for Pharmaceuticals. (2025). *T/CQAP 3015-2025: Specification for production and quality control of human mesenchymal stem cell drugs*.